Glenmark Pharmaceuticals
Sustainability Report and Carbon Intensity Rankings
Is Glenmark Pharmaceuticals doing their part?
Their DitchCarbon score is 66
Glenmark Pharmaceuticals has a DitchCarbon Score of 66, indicating a moderate level of sustainability in their operations. This score reflects the company’s efforts to manage and reduce its carbon intensity. A higher score would suggest even greater success in minimizing their environmental impact through lower carbon emissions.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
Glenmark Pharmaceuticals is part of the industrial manufacturing sector, which has a carbon intensity ranking of very low. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.
Location emissions intensity
Very low
Low
Medium
High
Very high
Glenmark Pharmaceuticals, located in India, operates in a region with a very high carbon intensity rating. This suggests that the company’s sustainability efforts may be negatively impacted by the country’s high reliance on carbon-intensive energy sources.
Unlock 30+ emissions data points on Glenmark Pharmaceuticals
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on Glenmark Pharmaceuticals
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
24.71%
...this company is doing 24.71% better in emissions than the industry average.
Glenmark Pharmaceuticals, founded in 1977 and headquartered in Mumbai, operates within the global pharmaceutical industry. The company specializes in the discovery and development of novel treatments in oncology, respiratory, and dermatology, with a focus on unmet medical needs. Glenmark offers a range of generic medications, high-quality active pharmaceutical ingredients (APIs), and advanced biologics through its proprietary BEAT platform, impacting over 100 million patients annually.
emission intelligence's platform recommendations for Glenmark Pharmaceuticals
Glenmark Pharmaceuticals should foster collaboration with industry partners to exchange best practices and resources, which could lead to a 35% reduction in their Scope 3 emissions.
Good news, Glenmark Pharmaceuticals has embraced SBTi commitments
Glenmark Pharmaceuticals has established Science Based Targets initiative (SBTi) commitments to significantly reduce its greenhouse gas emissions from both direct operations and purchased energy. These commitments align with the global effort to limit temperature rise to well below 2°C above pre-industrial levels.
Participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.